Antibodies have proven to be effective vehicles for the targeting of NCAM1, and various antibody–drug conjugates have been developed to deliver cytotoxic substances specifically to small cell lung carcinoma cells via NCAM1 targeting [11,13,14]. This evidence concerns the gene NCAM1 and small cell lung carcinoma.